Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Weiguo Su, Zhiping Li et al.|The Lancet Oncology|2020Cited by 193
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Weiguo Su, Lin Shen et al.|European Journal of Cancer|2025Cited by 4
Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.Chunmei Bai, Weiguo Su, Jianming Xu et al.|Journal of Clinical Oncology|2020Cited by 1